Ovid Therapeutics News

TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating

TD Cowen analyst Ritu Baral maintains $Ovid Therapeutics(OVID.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.8% and a total average return of 8.2% over the pas

Futu NewsJul 3 18:31 · Ratings

A Quick Look at Today's Ratings for Ovid Therapeutics(OVID.US), With a Forecast Between $2 to $5

On Jul 02, major Wall Street analysts update their ratings for $Ovid Therapeutics(OVID.US)$, with price targets ranging from $2 to $5.TD Cowen analyst Ritu Baral maintains with a buy rating.BTIG analy

Futu NewsJul 2 21:00 · Ratings

TD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

TipRanksJul 2 19:26

HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $3 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ovid Therapeutics (NASDAQ:OVID) with a Buy and maintains $3 price target.

BenzingaJul 2 18:23

Ovid Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 252.94% HC Wainwright & Co. $3 → $3 Reiterates Buy → Buy 06/18/2024 488.24% BTIG $11 → $5 Maint

BenzingaJul 2 18:22

Buy Rating Affirmed for Ovid Therapeutics Following Promising Phase 1 Results of OV888/GV101

TipRanksJul 2 18:17

Ovid Therapeutics' Promising Drug Safety and Biomarker Developments Garner Buy Rating

TipRanksJul 2 09:15

Buy Rating for Ovid Therapeutics Backed by Strong Clinical Data and Strategic Management

TipRanksJul 2 00:55

Express News | Ovid: Phase 2 Study for Treatment of Cerebral Cavernous Malformations Is Expected to Initiate in H2

BreakingsJul 1 20:00

Express News | Ovid Therapeutics Inc - No Serious Adverse Events Reported in Phase 1 Study

BreakingsJul 1 20:00

Express News | Ovid Therapeutics Inc - Phase 1 Study for Ov888/Gv101 Capsule Meets Its Objective

BreakingsJul 1 20:00

Express News | Ovid Therapeutics and Graviton Bioscience Announce Topline Data From a Phase 1 Clinical Trial Studying Ov888/Gv101 Capsule, a Potential First-in-Class Therapy for Cerebral Cavernous Malformations

BreakingsJul 1 20:00

Ovid Therapeutics to Cut WorKforce by 43%

By Sabela Ojea Ovid Therapeutics said it is cutting about 43% of its workforce, or 17 employees, to extend its cash runway. The biopharmaceutical company on Friday said that it expects to incur into

WSJJun 29 05:14

Express News | Ovid Therapeutics - Believes That Its Cash Runway Will Be Sufficient to Fund Its Operations Into the First Half of 2026

BreakingsJun 29 04:04

Express News | Ovid Therapeutics Inc - Anticipates a One-Time Severance-Related Charge Associated With Workforce Reduction to Be Approximately $4.0 Mln

BreakingsJun 29 04:03

Express News | Ovid Therapeutics Inc - Majority of Cash Payments Related to Restructuring Will Be Substantially Complete by End of Q2 2025.

BreakingsJun 29 04:03

Express News | Ovid Therapeutics Inc - Expects That Execution of Workforce Reduction Will Be Substantially Complete by End of Q3 of 2024

BreakingsJun 29 04:03

Express News | Ovid Therapeutics Inc - Will Reduce Its Workforce by 17 People, or Approximately 43% of Company's Existing Headcount

BreakingsJun 29 04:02

A Quick Look at Today's Ratings for Ovid Therapeutics(OVID.US), With a Forecast Between $2 to $3

On Jun 19, major Wall Street analysts update their ratings for $Ovid Therapeutics(OVID.US)$, with price targets ranging from $2 to $3.TD Cowen analyst Ritu Baral maintains with a buy rating.Oppenheime

Futu NewsJun 19 21:00 · Ratings

Oppenheimer Cuts Ovid to Perform, Cites Uncertainty Over Lead Drug

Seeking AlphaJun 19 00:27